TWST Quote, Financials, Valuation and Earnings

Enovis Corp. has a net margin of -27.41% compared to Twist Bioscience Corp.'s net margin of -104%. Twist Bioscience Corp.'s return on equity of -16.74% beat Enovis Corp.'s return on equity of -52.07%.

Twist Bioscience Corp. has a consensus price target of $35.88, signalling upside risk potential of 6.83%. On the other hand Enovis Corp. has an analysts' consensus of $47.00 which suggests that it could grow by 74.98%. Given that Enovis Corp. has higher upside potential than Twist Bioscience Corp., analysts believe Enovis Corp. is more attractive than Twist Bioscience Corp..

Twist Bioscience Corp. has a beta of 2.242, which suggesting that the stock is 124.157% more volatile than S&P 500. In comparison Enovis Corp. has a beta of 1.284, suggesting its more volatile than the S&P 500 by 28.371%.

Twist Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Twist Bioscience Corp. pays -- of its earnings as a dividend. Enovis Corp. pays out -- of its earnings as a dividend.

Twist Bioscience Corp. quarterly revenues are $99M, which are smaller than Enovis Corp. quarterly revenues of $548.9M. Twist Bioscience Corp.'s net income of -$27.1M is higher than Enovis Corp.'s net income of -$570.9M. Notably, Twist Bioscience Corp.'s price-to-earnings ratio is -- while Enovis Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Twist Bioscience Corp. is 5.36x versus 0.68x for Enovis Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Lifeward Ltd. has a net margin of -27.41% compared to Twist Bioscience Corp.'s net margin of -51.17%. Twist Bioscience Corp.'s return on equity of -16.74% beat Lifeward Ltd.'s return on equity of -150.63%.

Twist Bioscience Corp. has a consensus price target of $35.88, signalling upside risk potential of 6.83%. On the other hand Lifeward Ltd. has an analysts' consensus of $7.25 which suggests that it could grow by 1043.17%. Given that Lifeward Ltd. has higher upside potential than Twist Bioscience Corp., analysts believe Lifeward Ltd. is more attractive than Twist Bioscience Corp..

Twist Bioscience Corp. has a beta of 2.242, which suggesting that the stock is 124.157% more volatile than S&P 500. In comparison Lifeward Ltd. has a beta of 0.010, suggesting its less volatile than the S&P 500 by 99.011%.

Twist Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifeward Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Twist Bioscience Corp. pays -- of its earnings as a dividend. Lifeward Ltd. pays out -- of its earnings as a dividend.

Twist Bioscience Corp. quarterly revenues are $99M, which are larger than Lifeward Ltd. quarterly revenues of $6.2M. Twist Bioscience Corp.'s net income of -$27.1M is lower than Lifeward Ltd.'s net income of -$3.2M. Notably, Twist Bioscience Corp.'s price-to-earnings ratio is -- while Lifeward Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Twist Bioscience Corp. is 5.36x versus 0.30x for Lifeward Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -27.41% compared to Twist Bioscience Corp.'s net margin of -862.39%. Twist Bioscience Corp.'s return on equity of -16.74% beat VolitionRX Ltd.'s return on equity of --.

Twist Bioscience Corp. has a consensus price target of $35.88, signalling upside risk potential of 6.83%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 773.02%. Given that VolitionRX Ltd. has higher upside potential than Twist Bioscience Corp., analysts believe VolitionRX Ltd. is more attractive than Twist Bioscience Corp..

Twist Bioscience Corp. has a beta of 2.242, which suggesting that the stock is 124.157% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Twist Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Twist Bioscience Corp. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Twist Bioscience Corp. quarterly revenues are $99M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Twist Bioscience Corp.'s net income of -$27.1M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Twist Bioscience Corp.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Twist Bioscience Corp. is 5.36x versus 17.27x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -27.41% compared to Twist Bioscience Corp.'s net margin of 3.93%. Twist Bioscience Corp.'s return on equity of -16.74% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Twist Bioscience Corp. has a consensus price target of $35.88, signalling upside risk potential of 6.83%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.8%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Xtant Medical Holdings, Inc. is more attractive than Twist Bioscience Corp..

Twist Bioscience Corp. has a beta of 2.242, which suggesting that the stock is 124.157% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Twist Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Twist Bioscience Corp. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Twist Bioscience Corp. quarterly revenues are $99M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Twist Bioscience Corp.'s net income of -$27.1M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Twist Bioscience Corp.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Twist Bioscience Corp. is 5.36x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.